OVERVIEW

Call to Action: Chronic HBV Monitoring and Hepatocellular Carcinoma (HCC) Surveillance in Primary Care Settings is organized by CME Outfitters, LLC and will be held from Oct 18, 2018 - Oct 18, 2019.

Target Audience
Primary care physicians, internists, gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with HBV.

Credit Information
CME Credit (Physicians):
CME Outfitters, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Statement of Need
The National Strategy for the Elimination of Hepatitis B and C Phase 2 Report was released in March 2017 and indicated that better attention to prevention, screening, and treatment of hepatitis B and C could eliminate the burden of these diseases and prevent nearly 90,000 deaths by 2030.

Regularly monitoring of disease status with HBV DNA is imperative to determine the need for antiviral therapy, and the guideline for HCC recommends surveillance of high risk persons every 6 months. Repeat lab testing is recommended as well, but this testing should not take the place of treatment consideration.

This CME Outfitters mobile case series is designed to help primary care and internal medicine clinicians improve their knowledge, confidence, and performance in employing monitoring strategies to assess treatment effectiveness in patients with HBV.

Learning Objectives
At the end of this CE activity, participants should be able to:
• Employ monitoring strategies to assess treatment effectiveness in patients with HBV, including evaluation of continued virological response and antiviral resistance.
• Identify evidence-based methods for the surveillance of the development of HCC in patients with chronic HBV.

Additional details will be posted as soon as they are available.